Sutro Biopharma (STRO)

Sutro Biopharma, Inc. (STRO) is a pioneering biopharmaceutical company founded in 2003, and headquartered in South San Francisco, California. Sutro is dedicated to creating new therapies with the potential to transform both the lives of patients and the paradigm of cancer care in general. The company is at the forefront of drug discovery and development, integrating cell-free protein synthesis and site-specific conjugation technologies to produce a new generation of precision oncology medicines.

Over the years, Sutro Biopharma has distinguished itself with a unique platform, referred to as XpressCF+™. This platform is the only cell-free biologics development approach that can generate not only proteins but also site-specifically conjugated payloads, without the need for living cells. Using this cell-free technology, the company can design, develop, and manufacture multiple types of biologic products, including next-generation cancer therapeutics like antibody-drug conjugates (ADCs), bispecific antibodies, and cytokine derivatives.

The pipeline of Sutro Biopharma boasts a broad range of preclinical and clinical-stage candidates. This includes their lead product candidate, STRO-001, which is in an ongoing Phase 1 clinical trial for patients with B-cell malignancies. Additionally, the company has STRO-002, a folate receptor alpha (FolRα)-targeting ADC, which is in a Phase 1 clinical trial for patients with advanced ovarian and endometrial cancers.

Apart from its in-house programs, Sutro Biopharma has also established strategic collaborations to leverage its technology platform. A notable partnership is with global pharmaceutical company Merck, focused on the discovery and development of cytokine derivatives for the treatment of cancer and autoimmune disorders.

Sutro Biopharma is united by a team of experienced and dedicated leaders who are navigating the company toward innovative breakthroughs in cancer treatment. The company has an unwavering commitment to improve the lives of cancer patients and believes that their science and technology can lead to a new generation of oncology therapeutics that achieves this vision.

In terms of financial performance, the company runs on the typical biopharmaceutical business model, investing heavily in research and development to generate future revenue via the successful commercialization of its drug candidates. As of end 2020, Sutro Biopharma reported steady progress in its pipeline with sufficient operating capital, positioning it for sustained success in its mission to alter the landscape of cancer treatment. The stock of Sutro Biopharma, Inc. trades under the ticker symbol STRO on Nasdaq, indicating its growth potential in the public market.